Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Techknow Conference Oct 2019

21 slides from Neuroscientific Biopharmaceuticals's conference presentation, Oct 24, 2019

  1. Slide 1: ASX Announcement: Correction to Presentation

    For personal use only ASX ANNOUNCEMENT ASX:NSB Correction to Presentation released 22 October 2019 NeuroScientific Biopharmaceuticals Limited (ASX:NSB) wishes to issue the following correction pertaining to key milestones included in the “NSB - Techknow Conference Presentation Oct 19” released on 22

  2. Slide 2: NeuroScientific Biopharmaceuticals Ltd

    For personal use only NeuroScientific Biopharmaceuticals Ltd ASX.NSB Novel drug therapies for neurodegenerative conditions

  3. Slide 3: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  4. Slide 4: Corporate Overview: Capital Structure

    3 CORPORATE OVERVIEW For personal use only Capital Structure ▹ Completed IPO listing @20c on ASX code NSB the ASX on the 27 July 2018 Shares on issue 78.3M ▹ Lead candidate funded through to Options (20c exp 7/03/2021) 60.7M completion of Phase I Price (close 21/10/2019) $0.235 $0.435 12m High ▹ Pip

  5. Slide 5: Leadership Team

    4 LEADERSHIP TEAM For personal use only MATT LIDDELOW MPharm STEPHEN QUANTRILL MBA ANTON UVAROV PhD BRIAN LEEDMAN MBA 13+ years experience 20 years’ experience in Founding director of Actinogen an Co-founder of ResApp Health, commercialising medical devices corporate advisory and advanced Alzheimer’

  6. Slide 6: Treatment Markets with Unmet Need

    5 TREATMENT MARKETS WITH UNMET NEED For personal use only Alzheimer’s disease Optic nerve conditions 48M people globally have dementia 5% of population suffer vision loss due to 70% of dementias damaged optic nerve Alzheimer’s disease 60M people US $818B global affected by glaucoma economic burden U

  7. Slide 7: Alzheimer's Disease: The need for novel therapeutics

    6 ALZHEIMER’S DISEASE: The need for novel therapeutics For personal use only Drugs targeting the beta-amyloid protein have all failed in late-stage clinical trials… ▪ Pathology of Alzheimer’s disease still not definitive ▪ Drugs may have been administered too late ▪ Patient selection for clinical tr

  8. Slide 8: Lead Candidate: EmtinB

    7 LEAD CANDIDATE: EMTINB For personal use only NOVEL ▪ Modeled on Metallothionein (MT-II) - a well known neuroprotective and neurogenerative compound, with EmtinB showing superior drug properties ▪ Binds LRP-1 receptors – novel Mechanism of Action (MOA) ▪ Stops cell death & stimulates regeneration V

  9. Slide 9: Evolution of EmtinB

    8 EVOLUTION OF EMTINB For personal use only MT-II Structure EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain ▹ 61 amino acid length ▹ 14 amino acid length ▹ Synthesised as a ▹ Binds divalent metal ions ▹ Isolated from the β- dendrimer: ▹ Difficult to manufacture domain of MT-II protein ▪ In

  10. Slide 10: EmtinB Mechanism of Action: Binding LRP-1 receptor

    9 EMTINB MECHANISM OF ACTION: Binding LRP-1 receptor For personal use only

  11. Slide 11: EmtinB Scientific Data: Preclinical survival

    10 EMTINB SCIENTIFIC DATA Preclinical survival For personal use only Cortex Hippocampus *** ** Hippocampus: Alzheimer’s model ****

  12. Slide 12: EmtinB Scientific Data: Preclinical regeneration

    11 EMTINB SCIENTIFIC DATA Preclinical regeneration For personal use only Cortex Hippocampus *** *** Hippocampus: injury model Spinal cord: injury model ** ***

  13. Slide 13: EmtinB Scientific Data: Spinal cord injury model

    12 EMTINB SCIENTIFIC DATA Spinal cord injury model For personal use only ▹ Primary neurons isolated from spinal cord tissue of adult rats ▹ EmtinB (30µg/mL) neuron regeneration >300% vs. untreated control ▹ EmtinB (30µg/mL) neuron regeneration >2x Copaxon®; marketed drug for Multiple Sclerosis ▹ Emt

  14. Slide 14: EmtinB Scientific Data: Preclinical animal models

    13 EMTINB SCIENTIFIC DATA Preclinical studies: animal models For personal use only Crosses the blood brain Slowed progression of disease barrier (memory impairment) by >80% in Alzheimer’s animal model Cognition: treatment for 48 days EmtinB 70% +7 Control 38% +5 0% 50% 100 %

  15. Slide 15: Supporting Scientific Data: Regenerating the optic nerve

    14 SUPPORTING SCIENTIFIC DATA Regenerating the optic nerve For personal use only ▹ Precursor to EmtinB (MT-II) stimulated regenerative growth of optic nerve after complete surgical transection ▹ Promotes axonal regeneration through an inhibitory environment in vivo Optic Nerve Growth No treatment –

  16. Slide 16: EmtinB Can be a Novel Treatment for Glaucoma

    EmtinB Can be a Novel Treatment for 15 Glaucoma with Disease-Modifying Potential For personal use only ▪ New data demonstrates the ability of EmtinB to penetrate the retina and optic nerve of the rabbit eye with no side effects ▪ Data from rabbit study also indicates that EmtinB could be developed i

  17. Slide 17: EmtinB Development Schedule

    16 EMTINB DEVELOPMENT SCHEDULE For personal use only 2019 2019 2019 2019 2020 2020 Q1 Q2 Q3 Q4 Q1 Q2 Alzheimer’s disease indication Preclinical safety & toxicology studies Additional AD animal efficacy study (CVN Alzheimer's Model) Phase I clinical study Ophthalmology indication Preclinical safety s

  18. Slide 18: Strategic Partnerships

    17 STRATEGIC PARTNERSHIPS For personal use only ▹ Partner for preclinical studies ▹ Partner for ophthalmology studies ▹ Managed >3300 unique compounds ▹ Developed 1st artificial cornea ▹ >500 IND/CTD programs in the last ▹ Developed 1st transgenic animal 5-years model for macular degeneration ▹ Offe

  19. Slide 19: Business Model

    18 BUSINESS MODEL For personal use only ▹ Company will seek to out-license EmtinB for late-stage clinical development ▹ Potential for multiple treatment indications will be attractive to “big pharma”

  20. Slide 20: Key Milestones

    19 KEY MILESTONES For personal use only OCT-19 DEC-19 Report on ocular tissue Results on efficacy study distribution study in in glaucoma pig model rabbits. Nov-19 NOV/DEC -19 Results on additional Expected conclusion of efficacy study in CVN safety & toxicity studies Alzheimer’s model

  21. Slide 21: NeuroScientific Biopharmaceuticals Ltd

    For personal use only NeuroScientific Biopharmaceuticals Ltd ASX.NSB Novel drug therapies for neurodegenerative conditions

NeuroScientific Biopharmaceuticals — Techknow Conference Oct 2019 on 6ix